Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fasted Conditions

This study has been completed.
Sponsor:
Information provided by:
Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier:
NCT00939536
First received: July 13, 2009
Last updated: August 15, 2013
Last verified: August 2013
  Purpose
  • Objective:

    • To compare the rate and extent of absorption of Zolpidem Tablets 10mg: Test Product: Zolpidem Tablets 10mg manufactured by Torrent Pharmaceuticals Limited, India Reference Product: Ambien® Tablets 10 mg (Reference Listed Drug) manufactured by Sanofi- Synthelabo Inc. under fasting conditions in 24 healthy, adult, human subjects.
  • Study Design:

    • Open label, randomized, two-period, two-treatment, two-sequence single dose crossover design.

Condition Intervention Phase
Healthy
Drug: Zolpidem Tartrate Tablets 10 mg
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Official Title: Studies in Fasted Healthy, Normal Subjects to Compare the Single Dose Bio-availability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets

Resource links provided by NLM:


Further study details as provided by Torrent Pharmaceuticals Limited:

Primary Outcome Measures:
  • Maximum Plasma Concentration (Cmax) [ Time Frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose. ] [ Designated as safety issue: No ]
    The maximum or peak concentration that the drug reaches in the plasma

  • Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] [ Time Frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose. ] [ Designated as safety issue: No ]
    The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)

  • The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞) [ Time Frame: plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose. ] [ Designated as safety issue: No ]
    The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.


Enrollment: 24
Study Start Date: June 2005
Study Completion Date: July 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Torrent's Zolpidem Tartrate Tablets 10 mg
Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
Drug: Zolpidem Tartrate Tablets 10 mg
Active Comparator: Sanofi-Synthelabo's Ambien® 10 mg Tablets
Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
Drug: Zolpidem Tartrate Tablets 10 mg

Detailed Description:

Open label, randomized, two-period, two-treatment, two-sequence single dose

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  1. Male and female subjects in the range of 18 - 45 years of age.
  2. Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart. (Appendix A)
  3. Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and body temperature)
  4. Subjects with normal findings as determined by hematological tests, serum chemistry, urine analysis, ECG and X-ray.
  5. Willingness to follow the protocol requirement as evidenced by written, informed consent.
  6. Agreeing to, not using any medication (prescription and over the counter), including vitamins and minerals for 15 days prior to study and during the course of the study.
  7. No history or presence of significant alcoholism or drug abuse in the past one year.
  8. Non-smokers, ex smokers and light smokers will be included. "Light smokers are defined as someone smoking 10 cigarettes or less per day, ex smokers as someone who completely stopped smoking for at least 3 months.

Exclusion Criteria:

  1. Requiring medication for any ailment including enzyme-modifying drugs Use of any drugs known to induce or inhibit hepatic drug metabolism (e.g.s, inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors: SSRIs, cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication.
  2. Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
  3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic diseases.
  4. History of psychiatric disorder or history of suicide attempt.
  5. Participation in a clinical drug study or bioequivalence study 90 days prior to present study.
  6. History of malignancy or other serious diseases.
  7. Refusal to abstain from food for ten (10) hours prior to study drug administration the day of each study period and for four (4) additional hours each, post dose.
  8. Refusal to abstain from water for one (1) hour prior to study drug administration the day of each study period and for two (2) additional hour, post dosing.
  9. Any contraindication to blood sampling.
  10. Refusal to abstain from smoking or consumption of tobacco products 24 hours before dosing until last sample collection of each period. Habituation of tobacco necessitating uninterrupted tobacco consumption.
  11. Use of xanthine-containing beverages or food for 48 hours prior to each drug dose.
  12. Blood donation 90 days prior to the commencement of the study.
  13. Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.
  14. Known history of allergic reactions to zolpidem or other related drugs.
  15. History of drug abuse in the past one year.
  16. Use of prescription medication within 14 days prior to administration of study medication or over the counter products (including natural food supplements, vitamins, garlic as a supplement) within 2 weeks prior to administration of study medication, except for topical products without systemic absorption.
  17. Pregnant and lactating women.

    • At the time of screening, prior to enrollment, presence of pregnancy will be confirmed by urine pregnancy test.
    • Female subjects not confirming to using birth control measures, from the date of screening till the completion of the second period of the study. Abstinence, barrier methods (condom, diaphragm, etc.) are acceptable. Use of hormonal contraceptives either oral or implants will not be acceptable.
  18. Female subjects whose menstruation cycle coincides with the study periods.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00939536

Locations
India
Accutest Research Laboratories Pvt. Ltd.
Mumbai, Maharashtra, India
Sponsors and Collaborators
Torrent Pharmaceuticals Limited
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00939536     History of Changes
Other Study ID Numbers: US/05/003
Study First Received: July 13, 2009
Results First Received: July 22, 2009
Last Updated: August 15, 2013
Health Authority: United States: Institutional Review Board
India: Institutional Review Board

Additional relevant MeSH terms:
Zolpidem
Central Nervous System Agents
Central Nervous System Depressants
GABA Agents
GABA Agonists
GABA-A Receptor Agonists
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014